WO2004087147A1 - 肺疾患の治療および/または予防剤 - Google Patents
肺疾患の治療および/または予防剤 Download PDFInfo
- Publication number
- WO2004087147A1 WO2004087147A1 PCT/JP2004/004597 JP2004004597W WO2004087147A1 WO 2004087147 A1 WO2004087147 A1 WO 2004087147A1 JP 2004004597 W JP2004004597 W JP 2004004597W WO 2004087147 A1 WO2004087147 A1 WO 2004087147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- asthma
- induced asthma
- lung disease
- eosinophilic
- induced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Definitions
- the present invention relates to a therapeutic and / or therapeutic agent for pulmonary diseases exhibiting eosinophilic inflammation (eg, bronchial asthma, eosinophilic pneumonia, etc.).
- eosinophilic inflammation eg, bronchial asthma, eosinophilic pneumonia, etc.
- An object of the present invention is to provide 7- [2- (3,5-diglolo-4-pyridyl) -1-oxoethyl] -4-methoxyspiro [1,3-benzodioxol-1,2,1-cyclobeta].
- Pneumonia] or a pharmacologically acceptable salt thereof as an active ingredient which causes eosinophilic inflammation, lung disease (eg, antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, toxic substance-induced asthma, etc.)
- lung disease eg, antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, toxic substance-induced asthma, etc.
- bronchial asthma chronic eosinophilic pneumonia, acute eosinophilic pneumonia, etc.
- the present invention relates to the following (1) to (15).
- Pulmonary diseases with eosinophilic inflammation consist of antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, toxicant-induced asthma, chronic eosinophilic pneumonia and acute eosinophilic pneumonia
- the therapeutic and / or prophylactic agent for pulmonary disease according to (1) which is a pulmonary disease selected from the group.
- the lung disease exhibiting eosinophilic inflammation is a lung disease selected from the group consisting of antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, and toxic substance-induced asthma
- Pulmonary diseases with eosinophilic inflammation consist of antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, toxicant-induced asthma, chronic eosinophilic pneumonia, and acute eosinophilic pneumonia
- the method for treating and preventing or preventing lung disease according to (6) which is a lung disease selected from the group.
- the lung disease exhibiting eosinophilic inflammation is a lung disease selected from the group consisting of antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, and toxic substance-induced asthma
- lung disease presenting eosinophilic inflammation is bronchial asthma or eosinophilic pneumonia
- Pulmonary diseases with eosinophilic inflammation consist of antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, toxicant-induced asthma, chronic eosinophilic pneumonia, and acute eosinophilic pneumonia 7— [2— (3,5-dichloro-1-4-pyridyl) -1-1-oxoethyl] -1-4-methoxyspiro [1,3, -benzodioxo-l- 2, described in (11), which is a lung disease selected from the group 1, -cyclopentane] or its pharmacologically acceptable salts
- the lung disease presenting eosinophilic inflammation is bronchial asthma (11).
- the lung disease exhibiting eosinophilic inflammation is a lung disease selected from the group consisting of antigen-induced asthma, exercise-induced asthma, cold-induced asthma, asvilin asthma and toxic substance-induced asthma
- the pharmacologically acceptable salts of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
- Pharmaceutically acceptable acid addition salts of compound (I) include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, and citrate
- examples of the pharmacologically acceptable metal salts include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, and aluminum salts.
- pharmacologically acceptable ammonium salts include, for example, ammonium salts and tetramethylammonium salts
- pharmacologically acceptable organic amine addition salts include: Addition salts such as morpholine, piperidine and the like can be mentioned, and pharmacologically acceptable amino acid addition salts include glycine, phenylalanine, lysine, aspartic acid, and glumic acid. Any addition salts, and the like. Next, a method for producing the compound (I) will be described.
- Compound (I) can be produced by the method described in W096 / 036624.
- Compound (I) may have stereoisomers such as tautomers, and the therapeutic and / or prophylactic agent for bronchial asthma of the present invention includes all possible isomers including these, and Mixtures of these can be used.
- compound (I) when it is desired to obtain a salt of compound (I), when compound (I) is obtained in the form of a salt, it may be purified as it is, and when compound (I) is obtained in a free form, compound (I) may be dissolved in an appropriate solvent May be dissolved or suspended in water and isolated or purified by adding an acid or a base.
- the compound (d) and its pharmacologically acceptable salts may exist in the form of adducts with water or various solvents, and these adducts are also used in the treatment of bronchial asthma according to the present invention. / Or can be used as a prophylactic agent.
- Test Example 1 Inhibitory Effect on Rat Antigen-Induced Airway Eosinophil Infiltration The 'test was performed according to a known method [Palmanary' Pulmonary Pharmacology ', 1995, 8 vol. 83].
- active sensitization was performed by intraperitoneal administration of 0.5 mL of a pertussis killed bacterial suspension (2 ⁇ 10 1 Q / ImL physiological saline, manufactured by Kaken Pharmaceutical Co., Ltd.).
- the rats were placed in a plastic chamber (30 ⁇ 50 ⁇ 30 cm), and antigen exposure was performed by spraying a 1% w / v 0% saline solution for 10 minutes.
- An ultrasonic nebulizer (manufactured by OMRON) was used for spraying.
- a preparation comprising lmg of lactose (Pharma tose 325 M: registered trademark, manufactured by DMV) per lmg of compound (I) (hereinafter referred to as compound (I) lactose preparation) was prepared by a conventional method.
- the compound (I) -lactose preparation was suspended in 0.125% w / v tyloxapol (Arevert: registered trademark, manufactured by Azdul Corporation) so that the concentration of the compound (I) was 0.5 mg / mL.
- the resulting suspension was further diluted with 0.125% w / v tyloxapol, Suspensions for administration of the compound (I) at an appropriate concentration were prepared.
- a solution prepared by dissolving lactose alone at a concentration of 2.5 mg / mL in 0.125% by weight of tyloxapol was prepared as a solvent for administration.
- the administration solvent or the suspension for administration of the compound (I) was intrabronchially administered to the left and right bronchi of the sensitizing rat 1 by 100, "L, respectively, for a total of 200 L.
- the suspension for administration of (I) was intrabronchially administered to sensitized rats, and the group sprayed with 1% by weight of OVA—physiological saline was administered to the compound (I) administration group, and the administration solvent was administered to the sensitized rats.
- a group sprayed intravenously and sprayed with 1% by weight Z volume% OVA-saline was designated as a solvent administration group, and a group sprayed with the administration solvent intrabronchially to sensitized rats and sprayed with saline was designated as a saline group.
- Bronchoalveolar lavage (BAL) was performed 24 hours after antigen exposure or saline spray. Anesthesia was performed by intraperitoneal administration of pentobarbi (Dainippon Pharmaceutical Co., Ltd.) to rats, and the alveolar cavity was washed with a saline solution through the trachea, and bronchoalveolar lavage fluid (BALF ).
- the total white blood cell count in BALF was measured using an automatic blood cell counter Yuichi (manufactured by Nihon Kohden Corporation).
- a smear of cells was prepared, stained with Giemsa, observed under an optical microscope, and the number of eosinophil cells was counted to calculate the ratio.
- the eosinophil count was calculated by multiplying the total leukocyte count by the eosinophil cell ratio.
- the inhibition rate (%) against the increase in the number of eosinophils in BALF was calculated according to the following.
- Inhibition rate (%) X100 number of eosinophils in solvent-administered group ⁇ number of eosinophils in physiological saline group The results are shown in Table 1. In addition, each value of the number of eosinophils shows an average value standard error.
- bronchial asthma is a disease characterized by eosinophilic airway inflammation [Clinical-Experimental Allergy (Cl in. Exp. All l.) ⁇ 2002, Vol. 32, p. 162], It is known that marked eosinophil infiltration into lung tissue and BALF is observed.
- Non-steroidal anti-inflammatory drugs such as aspirin, harmful substances such as diesel exhaust, antigens, exercise, and cold are considered to be factors that induce or exacerbate symptoms such as inflammation in asthma [Global Initiative] 'For'azuma (Global Init iat ive f or Asthma
- GINA Global Strategory or Asthma Management and Prevention
- eosinophil pneumonia is characterized by an increase in the number of eosinophils in blood, lungs, etc. [Molecular 'Medicine Today (Mo 1. Med. Today), 2000, 6 vol. p. 20].
- compound (I) or a pharmacologically acceptable salt thereof may be, for example, bronchial asthma such as antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, or harmful substance-induced asthma, or chronic eosinophils. It is considered to be effective as a therapeutic and / or prophylactic agent for pulmonary diseases exhibiting eosinophilic inflammation such as atopic pneumonia and acute eosinophilic pneumonia.
- Test Example 2 Effect of Continuous Administration on Rat Antigen-Induced Airway Eosinophil Infiltration Inhibition The test was performed according to the method described in Test Example 1.
- a suspension for administration of compound (I) and a solvent for administration were prepared in the same manner as in Test Example 1.
- a solvent for administration or a suspension for administration of compound (I) was prepared in the same manner as in Test Example 1. 100 L each was applied to the left and right bronchus of the sensitized rat, a total of 200 L, once a day for 7 consecutive days. And administered intrabronchially. The final dose was given 30 minutes before antigen exposure.
- the compound (I) administration suspension was intrabronchially administered to sensitized rats, and the group sprayed with 1% w / v OVA-saline was administered to the compound (I) administration group and the administration solvent was administered to the sensitized rats.
- the group administered intrabronchially and sprayed with 1% Z-volume OVA-saline was designated as the solvent group, and the group treated with the administered solvent intrabronchially to sensitized rats and sprayed with saline was referred to as the saline group. did.
- Table 2 shows the results. In addition, each value of the number of eosinophils shows an average value soil standard error.
- Compound (I) exhibited an inhibitory effect on eosinophil infiltration even when continuously administered at a low dose.
- compound (I) or a pharmacologically acceptable salt thereof can be administered continuously to give, for example, antigen-induced asthma, exercise-induced asthma, cold-induced asthma, and aspirin asthma.
- pulmonary diseases with eosinophilic inflammation such as bronchial asthma such as breath and harmful substance-induced asthma, chronic eosinophilic pneumonia and acute eosinophilic pneumonia it is conceivable that.
- Test Example 3 Long-lasting effect on the inhibition of rat antigen-induced airway eosinophil infiltration
- Test Example 1 The test was performed according to the method described in Test Example 1.
- a suspension for administration of compound (I) and a solvent for administration were prepared in the same manner as in Test Example 1.
- a suspension for administration of compound (I) or an administration solvent was administered to the sensitized rat prepared in the same manner as in Test Example 1, and 1% w / v OVA—physiological saline (antigen) or physiological saline was added. Sprayed.
- each of the suspensions for administration of compound (I) was applied to the left and right bronchi on the left and right bronchus, respectively, for a total of 200 L / L (100 L each).
- Intrabronchially administered group administered compound (I) administration group administration vehicle administered intravenously 1 hour before antigen exposure
- Vehicle administered group administered 1 hour before antigen exposure physiological saline sprayed 1 hour
- the group to which the solvent was intrabronchially administered was the physiological saline group.
- BAL was performed for each group in the same manner as in Test Example 1 to obtain BALF for each group.
- the number of eosinophils in BALF was calculated, and the inhibition rate (%) against the increase in the number of eosinophils in BALF by administration of compound (I) was determined.
- Table 3 shows the results. In addition, each value of the number of eosinophils shows an average value soil standard error. '' Table 3
- compound (I) or a pharmacologically acceptable salt thereof includes, for example, bronchial asthma such as antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, and harmful substance-induced asthma, and chronic eosinophils. It can be used as a therapeutic and / or prophylactic agent for pulmonary diseases presenting with eosinophilic inflammation such as atopic pneumonia and acute eosinophilic pneumonia, and its action is expected to last for a long time.
- sustained action of compound (I) shown here is considered to be useful for improving Nocturnal Asthma (nighttime asthma) and morning dip (morning dip in asthma).
- Can be any sustained action of compound (I) shown here is considered to be useful for improving Nocturnal Asthma (nighttime asthma) and morning dip (morning dip in asthma).
- Compound (I) or a pharmacologically acceptable salt thereof can be administered alone as it is, but it is usually desirable to provide it as various pharmaceutical preparations. These pharmaceutical preparations are used for animals and humans. '
- the pharmaceutical preparation according to the present invention can contain Compound (I) or a pharmaceutically acceptable salt thereof alone or as a mixture with any other active ingredient for treatment as an active ingredient.
- Such pharmaceutical preparations are prepared by mixing the active ingredient with one or more pharmacologically acceptable carriers and by any method well known in the technical field of pharmaceuticals.
- the administration route is preferably the one that is most effective in treatment, and may be oral or parenteral, for example, intravenous, intratracheal, or transdermal.
- tablets suitable for oral administration include excipients such as lactose and mannitol, disintegrants such as starch, lubricants such as magnesium stearate, binders such as hydroxypropylcellulose, and interfaces such as fatty acid esters. It can be produced using an activator, a plasticizer such as glycerin, and a preservative such as benzoic acid and p-hydroxybenzoic acid esters.
- Suitable for parenteral administration are preferably composed of sterile aqueous preparations containing the active compound, which is preferably isotonic with the blood of the recipient.
- a solution for injection can be prepared using a carrier comprising a mixture of glucose solutions and the like.
- Inhalants are prepared by dissolving the active ingredient in powder or liquid form, mixing it into an inhalation propellant or carrier, and filling it in an appropriate inhalation container such as a metered dose inhaler or dry powder inhaler.
- an appropriate inhalation container such as a metered dose inhaler or dry powder inhaler.
- an inhalation container such as a metered dose inhaler or dry powder inhaler.
- an inhalation propellant conventionally known ones can be widely used.
- Freon-based gas such as CFC 1, C 1 -18, 1, 1, 1, 1, 2-tetrafluoroethane; CFC alternative gas such as HFA-227 s HF A-134a; Examples include hydrocarbon gases such as propane, isobutane, and n-butane, getyl ether, nitrogen gas, and carbon dioxide gas.
- carrier conventionally known carriers can be widely used, and examples thereof include sugars, sugar alcohols, and amino acids. Lactose, D-mannitol and the like are preferable.
- the dosage form suitable for the external preparation is not particularly limited, and the active ingredient is dissolved or mixed and dispersed in the base ⁇ ] to form a cream, paste, jelly, gel, emulsion, liquid or the like. What is done (ointment, liniment, lotion, etc.), or a solution in which the active ingredient and transdermal absorption enhancer are dissolved or mixed and dispersed in a base, for example, a support such as polyethylene, polyester, polyethylene terephthalate Products spread on the top (such as cataplasms and tapes).
- a base for example, a support such as polyethylene, polyester, polyethylene terephthalate Products spread on the top (such as cataplasms and tapes).
- any pharmacologically acceptable base may be used, and conventionally known bases such as ointments, liniments, lotions and the like can be used.
- sodium alginate for example, sodium alginate; gelatin , Corn starch, tragacanth, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, xanthan gum, dextrin, carboxymethylstarch, polyvinyl alcohol, sodium polyacrylate, methoxethylen-maleic anhydride copolymer, polyvinyl ether, polyvinyl bi-lidone, etc.
- oils and fats such as beeswax, olive oil, cocoa oil, sesame oil, soybean oil, tobacco oil, peanut oil, beef oil, pork oil, and lanolin; petrolatums such as white petrolatum and yellow petrolatum S; paraffin; Hydro power one Bongeru ointment (e.g., (Trade name: Plastibase, manufactured by Taisho Pharmaceutical Co., Ltd.); higher fatty acids such as stearic acid; higher alcohols such as cetyl alcohol and stearyl alcohol; polyethylene glycol; and water.
- oils and fats such as beeswax, olive oil, cocoa oil, sesame oil, soybean oil, tobacco oil, peanut oil, beef oil, pork oil, and lanolin
- petrolatums such as white petrolatum and yellow petrolatum S
- paraffin paraffin
- Hydro power one Bongeru ointment e.g., (Trade name: Plastibase, manufactured by Taisho Pharmaceutical Co., Ltd.)
- higher fatty acids such
- the percutaneous absorption enhancer may be any pharmacologically acceptable agent, for example, alcohols such as methanol, ethanol, diethylene glycol and propylene glycol; polar solvents such as dimethyl sulfoxide and dodecyl pyrrolidone; Urea; esters such as ethyl laurate, isopropyl myristate, and cetyl octanoate; azone; and olive oil.
- inorganic fillers such as kaolin, bentonite, zinc oxide and titanium oxide; viscosity modifiers; antioxidants; pH regulators; humectants such as glycerin and propylene glycol may be added. Good.
- parenteral preparations are still selected from diluents, flavors, and excipients, disintegrants, lubricants, binders, surfactants, plasticizers, preservatives, etc. exemplified for oral preparations.
- One or more auxiliary components may be added.
- the dose and frequency of compound (I) or a pharmaceutically acceptable salt thereof will vary depending on the form of administration, age and weight of the patient, and the nature or severity of the condition to be treated.
- 0.01 mg to 1 g, preferably 0.5 to 10 Omg per adult is administered once to several times a day.
- 1 g to 100 Omgs per adult is preferably administered from 0.01 to: L0 Omg, more preferably from 0.05 to 2 Omg once or several times a day.
- parenteral administration such as intravenous administration, 1 to 100 mg, preferably 0.01 to 1 Omg per adult, once to several times a day
- a tablet having the following composition is prepared by a conventional method.
- Compound (I) 40 g) 286.8 g of lactose and 60 g of potato starch are mixed, and 12 Og of a 10% aqueous solution of hydroxypropyl cellulose is added thereto.
- the mixture is kneaded by a conventional method, granulated and dried, and then sized to obtain granules for tableting. This is magnesium stearate 1.
- An injection having the following composition is prepared by a conventional method.
- Compound (I) lg is dissolved in purified soybean oil, and purified egg yolk lecithin 1 and glycerin for injection 25 g are obtained.
- This mixture is kneaded and emulsified with distilled water for injection to 100 Oml in a conventional manner.
- the resulting dispersion was aseptically filtered using a 0.2 ⁇ m disposable membrane filter, and aseptically filled into glass vials in 2 ml portions. Containing 2 mg of ingredient).
- Pulmonary disease with eosinophilic inflammation containing a chemically acceptable salt as an active ingredient eg, bronchial asthma such as antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, harmful substance-induced asthma
- bronchial asthma such as antigen-induced asthma, exercise-induced asthma, cold-induced asthma, aspirin asthma, harmful substance-induced asthma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005504258A JPWO2004087147A1 (ja) | 2003-03-31 | 2004-03-31 | 肺疾患の治療および/または予防剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003094503 | 2003-03-31 | ||
JP2003-094503 | 2003-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087147A1 true WO2004087147A1 (ja) | 2004-10-14 |
Family
ID=33127391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004597 WO2004087147A1 (ja) | 2003-03-31 | 2004-03-31 | 肺疾患の治療および/または予防剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2004087147A1 (ja) |
TW (1) | TW200503706A (ja) |
WO (1) | WO2004087147A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06100446A (ja) * | 1990-10-15 | 1994-04-12 | Merck & Co Inc | (S)−α−フルオロメチル−ヒスチジン及びそのエステルを使用するぜん息の治療方法 |
WO1996036624A1 (fr) * | 1995-05-19 | 1996-11-21 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques contenant de l'oxygene |
WO1999037640A1 (fr) * | 1998-01-26 | 1999-07-29 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques oxygenes |
JP2002537383A (ja) * | 1999-02-25 | 2002-11-05 | メルク フロスト カナダ アンド カンパニー | Pdeiv阻害化合物、組成物および治療方法 |
JP2002538115A (ja) * | 1999-03-01 | 2002-11-12 | スミスクライン・ビーチャム・コーポレイション | 運動誘発喘息の治療方法 |
WO2002098880A1 (en) * | 2001-06-01 | 2002-12-12 | Bayer Healthcare Ag | 5-ethyl-imidazotriazinones |
WO2003016279A1 (fr) * | 2001-08-09 | 2003-02-27 | Tanabe Seiyaku Co., Ltd. | Composes polycycliques fusionnes |
WO2003066044A1 (de) * | 2002-02-08 | 2003-08-14 | Kyowa Hakko Kogyo Co., Ltd. | Neue arzneimittelkompositionen enthaltend neben anticholinergika heterocyclische verbindungen |
WO2004005276A1 (ja) * | 2002-07-03 | 2004-01-15 | Kyowa Hakko Kogyo Co., Ltd. | 1,3−ベンゾジオキソール−2−スピロシクロアルカン誘導体の製造法 |
-
2004
- 2004-03-31 TW TW093108847A patent/TW200503706A/zh unknown
- 2004-03-31 JP JP2005504258A patent/JPWO2004087147A1/ja not_active Withdrawn
- 2004-03-31 WO PCT/JP2004/004597 patent/WO2004087147A1/ja active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06100446A (ja) * | 1990-10-15 | 1994-04-12 | Merck & Co Inc | (S)−α−フルオロメチル−ヒスチジン及びそのエステルを使用するぜん息の治療方法 |
WO1996036624A1 (fr) * | 1995-05-19 | 1996-11-21 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques contenant de l'oxygene |
WO1999037640A1 (fr) * | 1998-01-26 | 1999-07-29 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques oxygenes |
JP2002537383A (ja) * | 1999-02-25 | 2002-11-05 | メルク フロスト カナダ アンド カンパニー | Pdeiv阻害化合物、組成物および治療方法 |
JP2002538115A (ja) * | 1999-03-01 | 2002-11-12 | スミスクライン・ビーチャム・コーポレイション | 運動誘発喘息の治療方法 |
WO2002098880A1 (en) * | 2001-06-01 | 2002-12-12 | Bayer Healthcare Ag | 5-ethyl-imidazotriazinones |
WO2003016279A1 (fr) * | 2001-08-09 | 2003-02-27 | Tanabe Seiyaku Co., Ltd. | Composes polycycliques fusionnes |
WO2003066044A1 (de) * | 2002-02-08 | 2003-08-14 | Kyowa Hakko Kogyo Co., Ltd. | Neue arzneimittelkompositionen enthaltend neben anticholinergika heterocyclische verbindungen |
WO2004005276A1 (ja) * | 2002-07-03 | 2004-01-15 | Kyowa Hakko Kogyo Co., Ltd. | 1,3−ベンゾジオキソール−2−スピロシクロアルカン誘導体の製造法 |
Non-Patent Citations (5)
Title |
---|
BILLAH M. ET AL.: "9-Methoxyquinolines as PDE4 inhibitors", BIOORG. MED. CHEM. LETT., vol. 12, 2002, pages 1617 - 1619, XP002982731 * |
BILLAH M. ET AL.: "Synthesis and profile of SCH351591, a novel PDE4 inhibitor", BIOORG. MED. CHEM. LETT., vol. 12, 2002, pages 1621 - 1623, XP002297088 * |
IKEMURA T. ET AL.: "Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eisinophila", J. PHARM. EXP. THER., vol. 294, no. 2, 2000, pages 701 - 706, XP002982732 * |
KUBOTA SHIGERU: "IL-5 kosankyu jumyo encho koka to saibonai cAMP josho ni yoru sono yokusei koka", TEIKYO MEDICAL JOURNAL, vol. 19, no. 6, 1996, pages 563 - 570, XP002982733 * |
WHELAN C.J.: "Prospects for development of new drugs for the therapy of respiratory diseases", DRUGS OF TODAY, vol. 32, no. 4, 1996, pages 295 - 311, XP000614333 * |
Also Published As
Publication number | Publication date |
---|---|
TW200503706A (en) | 2005-02-01 |
JPWO2004087147A1 (ja) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3024521C (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
US20070287689A1 (en) | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | |
WO2004096274A1 (ja) | 気道内投与剤 | |
JP2002534477A (ja) | メラガトランの新規使用 | |
WO2004087147A1 (ja) | 肺疾患の治療および/または予防剤 | |
WO2004112791A1 (ja) | 肺疾患の治療および/または予防剤 | |
JPH0426631A (ja) | 血管新生抑制剤 | |
JPWO2004087148A1 (ja) | 肺疾患の治療および/または予防剤 | |
CA3024522C (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
JPWO2004082683A1 (ja) | 慢性皮膚疾患の治療および/または予防剤 | |
WO2005056009A1 (ja) | 肺疾患治療剤 | |
JPH11130671A (ja) | アルドースレダクターゼ阻害剤 | |
JP2005047835A (ja) | 医薬組成物 | |
JPWO2004087149A1 (ja) | 医薬組成物 | |
WO2005032540A1 (ja) | N−(ベンゾイル)アミノ酸誘導体を有効成分とする呼吸器疾患治療剤 | |
WO2004087151A1 (ja) | 医薬組成物 | |
JPH11335272A (ja) | 呼吸機能障害の予防及び/又は治療用医薬組成物 | |
JP2005015354A (ja) | 気管支喘息の治療および/または予防剤 | |
JPH09227372A (ja) | 白血球の接着または浸潤抑制剤および炎症の予防または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504258 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |